Feedback

SUMOtherapeutics for Ischemic Stroke

ORCID
0000-0002-3529-2037
Affiliation
T. H. Chan School of Medicine, University of Massachusetts, Worcester, MA 01655, USA
Karandikar, Paramesh;
ORCID
0000-0002-8100-0517
Affiliation
Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA
Gerstl, Jakob V. E.;
Affiliation
Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA
Kappel, Ari D.;
Affiliation
Department of Neurosurgery, University Medicine Rostock, 18057 Rostock, Germany
Won, Sae-Yeon;
Affiliation
Department of Neurosurgery, University Medicine Rostock, 18057 Rostock, Germany
Dubinski, Daniel;
Affiliation
Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
Garcia-Segura, Monica Emili;
ORCID
0000-0002-3471-0575
Affiliation
Department of Neurosurgery, University Medicine Rostock, 18057 Rostock, Germany
Gessler, Florian A.;
Affiliation
Department of Neurosurgery, Boston Children’s Hospital, Boston, MA 02215, USA
See, Alfred Pokmeng;
ORCID
0000-0002-9396-5607
Affiliation
Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
Peruzzotti-Jametti, Luca;
Affiliation
Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA
Bernstock, Joshua D.

The small, ubiquitin-like modifier (SUMO) is a post-translational modifier with a profound influence on several key biological processes, including the mammalian stress response. Of particular interest are its neuroprotective effects, first recognized in the 13-lined ground squirrel ( Ictidomys tridecemlineatus ), in the context of hibernation torpor. Although the full scope of the SUMO pathway is yet to be elucidated, observations of its importance in managing neuronal responses to ischemia, maintaining ion gradients, and the preconditioning of neural stem cells make it a promising therapeutic target for acute cerebral ischemia. Recent advances in high-throughput screening have enabled the identification of small molecules that can upregulate SUMOylation, some of which have been validated in pertinent preclinical models of cerebral ischemia. Accordingly, the present review aims to summarize current knowledge and highlight the translational potential of the SUMOylation pathway in brain ischemia.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © 2023 by the authors.

Use and reproduction: